Redhill Biopharma (NASDAQ:RDHL) Stock Price Breaks Below Two Hundred Day Moving Average – What’s Next?
by Mitch Edgeman · The Markets DailyRedhill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report)’s share price passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $0.77 and traded as low as $0.5132. Redhill Biopharma shares last traded at $0.53, with a volume of 69,964 shares changing hands.
Analyst Ratings Changes
Separately, Weiss Ratings cut Redhill Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 6th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Redhill Biopharma currently has an average rating of “Sell”.
Check Out Our Latest Research Report on Redhill Biopharma
Redhill Biopharma Stock Down 5.6%
The business’s 50 day simple moving average is $0.60 and its 200-day simple moving average is $0.76.
About Redhill Biopharma
RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and infectious conditions. Founded in Israel, the company operated internationally, with activities in the United States and other markets through research, regulatory, commercial and licensing relationships.
RedHill’s commercial products included Talicia, a combination therapy approved in the United States for the treatment of Helicobacter pylori infection in adults, and Aemcolo, an extended-release antibiotic approved for certain cases of travelers’ diarrhea caused by noninvasive strains of Escherichia coli.